DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Defective DNA mismatch repair (MMR) occurs in approximately 15% of sporadic colorectal cancers (CRCs). Multiple retrospective studies have shown that patients with MMR-deficient CRCs have a more favorable stage-adjusted prognosis compared with those who have MMR-proficient tumors. Evidence also indicates that patients with MMR-deficient colon cancers do not benefit from treatment with adjuvant 5-fluorouracil chemotherapy. Furthermore, recent studies, including a pooled analysis, have validated the prognostic and predictive impact of MMR status in patients with stage II and III colon cancer who were treated in adjuvant chemotherapy trials. Given these data, it can be recommended that MMR status be determined and used to inform clinical decision-making for adjuvant chemotherapy in patients with stage II colon cancer.

Original languageEnglish (US)
Pages (from-to)174-177
Number of pages4
JournalNature Reviews Clinical Oncology
Volume7
Issue number3
DOIs
StatePublished - Mar 2010

Fingerprint

DNA Mismatch Repair
Adjuvant Chemotherapy
Colonic Neoplasms
Colorectal Neoplasms
Fluorouracil
Retrospective Studies
Drug Therapy
Neoplasms

ASJC Scopus subject areas

  • Oncology

Cite this

DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer. / Sinicrope, Frank A.

In: Nature Reviews Clinical Oncology, Vol. 7, No. 3, 03.2010, p. 174-177.

Research output: Contribution to journalArticle

@article{d55cbeac98b4460aad5dd22a25954095,
title = "DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer",
abstract = "Defective DNA mismatch repair (MMR) occurs in approximately 15{\%} of sporadic colorectal cancers (CRCs). Multiple retrospective studies have shown that patients with MMR-deficient CRCs have a more favorable stage-adjusted prognosis compared with those who have MMR-proficient tumors. Evidence also indicates that patients with MMR-deficient colon cancers do not benefit from treatment with adjuvant 5-fluorouracil chemotherapy. Furthermore, recent studies, including a pooled analysis, have validated the prognostic and predictive impact of MMR status in patients with stage II and III colon cancer who were treated in adjuvant chemotherapy trials. Given these data, it can be recommended that MMR status be determined and used to inform clinical decision-making for adjuvant chemotherapy in patients with stage II colon cancer.",
author = "Sinicrope, {Frank A}",
year = "2010",
month = "3",
doi = "10.1038/nrclinonc.2009.235",
language = "English (US)",
volume = "7",
pages = "174--177",
journal = "Nature Reviews Clinical Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer

AU - Sinicrope, Frank A

PY - 2010/3

Y1 - 2010/3

N2 - Defective DNA mismatch repair (MMR) occurs in approximately 15% of sporadic colorectal cancers (CRCs). Multiple retrospective studies have shown that patients with MMR-deficient CRCs have a more favorable stage-adjusted prognosis compared with those who have MMR-proficient tumors. Evidence also indicates that patients with MMR-deficient colon cancers do not benefit from treatment with adjuvant 5-fluorouracil chemotherapy. Furthermore, recent studies, including a pooled analysis, have validated the prognostic and predictive impact of MMR status in patients with stage II and III colon cancer who were treated in adjuvant chemotherapy trials. Given these data, it can be recommended that MMR status be determined and used to inform clinical decision-making for adjuvant chemotherapy in patients with stage II colon cancer.

AB - Defective DNA mismatch repair (MMR) occurs in approximately 15% of sporadic colorectal cancers (CRCs). Multiple retrospective studies have shown that patients with MMR-deficient CRCs have a more favorable stage-adjusted prognosis compared with those who have MMR-proficient tumors. Evidence also indicates that patients with MMR-deficient colon cancers do not benefit from treatment with adjuvant 5-fluorouracil chemotherapy. Furthermore, recent studies, including a pooled analysis, have validated the prognostic and predictive impact of MMR status in patients with stage II and III colon cancer who were treated in adjuvant chemotherapy trials. Given these data, it can be recommended that MMR status be determined and used to inform clinical decision-making for adjuvant chemotherapy in patients with stage II colon cancer.

UR - http://www.scopus.com/inward/record.url?scp=77749277597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77749277597&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2009.235

DO - 10.1038/nrclinonc.2009.235

M3 - Article

VL - 7

SP - 174

EP - 177

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

SN - 1759-4774

IS - 3

ER -